Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning

被引：0
|
作者：
Dimopoulos, Meletios Athanasios [1 ]
Landgren, Ola [2 ]
Siegel, David S. [3 ]
Grosicki, Sebastian [4 ]
Oriol, Albert [5 ,6 ]
Najdi, Rani [7 ]
Li, Chuang [7 ]
Mezzi, Khalid [7 ]
Shu, Natalie [8 ]
Quach, Hang [9 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece
[2] Univ Miami, Myeloma Div, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Hackensack Univ, Med Ctr, Multiple Myeloma Div, Hackensack, NJ USA
[4] Med Univ Silesia, Fac Hlth Sci, Dept Hematol & Canc Prevent, Katowice, Poland
[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[6] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
[7] Amgen Inc, Thousand Oaks, CA USA
[8] Paraxel, Chengdu, Peoples R China
[9] St Vincents Hosp Melbourne, East Melbourne, Australia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190726
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
    Usmani, Saad Z.
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David S.
    Weisel, Katja
    Yang, Hui
    Klippel, Zandra K.
    Zahlten-Kumeli, Anita
    Dimopoulos, Meletios A.
    BLOOD, 2019, 134
  • [12] CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE AND DARATUMUMAB (KDD) VERSUS CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: AN INDIRECT TREATMENT COMPARISON
    Wang, J.
    Patel, S.
    Yang, H.
    Chai, X.
    Bi, S.
    Du, M.
    VALUE IN HEALTH, 2024, 27 (12)
  • [13] Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
    Martin, Thomas G.
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
    Usmani, Saad Z.
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David
    Weisel, Katja
    Gavriatopoulou, Maria
    Oriol, Albert
    Rabin, Neil
    Nooka, Ajay
    Qi, Ming
    Beksac, Meral
    Jakubowiak, Andrzej
    Ding, Bifeng
    Zahlten-Kumeli, Anita
    Yusuf, Akeem
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2022, 23 (01): : 65 - 76
  • [15] Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease
    Mateos, Maria-Victoria
    Usmani, Saad Z.
    Quach, Hang
    Dimopoulos, Meletios-Athanasios
    Fonseca, Rafael
    McFadden, Ian
    Yusuf, Akeem
    Khurana, Monica
    Obreja, Mihaela
    Spencer, Andrew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S150 - S151
  • [16] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [17] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
    Xu, Jiadai
    Liu, Peng
    BLOOD, 2024, 144 : 7052 - 7053
  • [18] A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
    Richardson, Paul G.
    Amatangelo, Michael
    Berenson, James R.
    Cerchione, Claudio
    Dimopoulos, Meletios A.
    Hansen, Charlotte Toftmann
    Hwang, Soo Jeong
    Koo, Phillip
    Kuroda, Junya
    Oriol, Albert
    Orlowski, Robert Z.
    Quach, Hang
    Raab, Marc S.
    Rocci, Alberto
    Wang, Yue
    White, Darrell
    Yu, Brian
    Zhou, Zehua
    Katz, Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [19] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [20] CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF THE PHASE 3 ENDEAVOR STUDY BY AGE SUBGROUP
    Palumbo, A.
    Dimopoulos, M. A.
    Moreau, P.
    Chng, W. J.
    Goldschmidt, H.
    Hajek, R.
    Facon, T.
    Ludwig, H.
    Pour, L.
    Niesvizky, R.
    Oriol, A.
    Rosinol, L.
    Suvorov, A.
    Gaidano, G.
    Pika, T.
    Weisel, K.
    Gillenwater, H. H.
    Goranova-Marinova, V.
    Mohamed, N.
    Feng, S.
    Joshua, D.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
12345